In this excerpt from Tall Rounds®, Gianluca Torregrossa, MD, discusses minimally invasive and totally endoscopic coronary artery bypass grafting (TECAB), highlighting procedural advances that enable multi-vessel revascularization through less invasive approaches.

Looking to refer a patient? Please reach out to our Physician Referral team Mon. - Fri., 8 a.m. - 5 p.m. (ET) at 855.751.2469.

View the full Tall Rounds program. https://2207941.mediaspace.kaltura.com/category/Tall+Rounds/75663251

Steven Nissen, MD, and Luke Laffin, MD, discuss one-year follow-up data for CTX310, a CRISPR-Cas9 gene-editing therapy targeting ANGPTL3 to treat lipid disorders. They review the sustained reductions in LDL cholesterol and triglycerides, and the potential role of one-time gene-editing therapies in cardiovascular prevention and lipid management.

Read the article. https://consultqd.clevelandclinic.org/effects-of-crispr-cas9-gene-editing-for-dyslipidemia-endure-1-year

Steven Nissen, MD, and Ashish Sarraju, MD, discuss early clinical data on Kylo-11, a novel therapy that produced substantial reductions in lipoprotein(a) for up to one year after a single injection. Lowering lipoprotein(a), a genetically determined cardiovascular risk factor linked to atherosclerotic disease and aortic stenosis, remains an important focus for preventive cardiology. Learn about the new drug's mechanism and safety findings.

Looking to refer a patient? Please reach out to our Physician Referral team Mon. - Fri., 8 a.m. - 5 p.m. (ET) at 855.751.2469.